Bavarian Nordic A/S

Equities

BAVA

DK0015998017

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 10:59:52 2024-02-26 am EST 5-day change 1st Jan Change
176.9 DKK +0.86% Intraday chart for Bavarian Nordic A/S +5.49% -0.31%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bavarian Nordic Receives Accelerated Assessment Status for Chikungunya Vaccine MT
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial MT
Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024 CI
Nordic Stocks Rose Friday; Bavarian Nordic Topped Leaders DJ
Stigma, regulatory barriers delay mpox response in country that needs it most RE
Nordic Shares Closed Up Monday; Better Collective Topped Leaders DJ
Nordic Shares Closed Down Thursday; Better Collective Fell Furthest DJ
Transcript : Bavarian Nordic A/S, Q3 2023 Earnings Call, Nov 16, 2023
Bavarian Nordic Confirms FY23 Revenue Growth Outlook MT
Bavarian Nordic A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023 CI
Bavarian Nordic Wins US Regulatory Nod for Mpox Vaccine in Adults MT
US CDC panel recommends Bavarian Nordic's vaccine for adults at risk of mpox RE
Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk CI
Nordic Shares Decreased Tuesday; Beijer Ref Series B Posted Biggest Loss DJ
Bavarian Nordic Receives EUR11 Million Smallpox Vaccine Contract MT
Bavarian Nordic A/S Wins Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve CI
Bavarian Nordic Flags Lack of Commercial Opportunity from COVID-19 Booster Amid New Variants MT
Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2 CI
Nordic Stocks Rose Tuesday; Bavarian Nordic Climbed Highest DJ
Nordic Stocks Decreased Friday; Surgical Science Sweden Fell Furthest DJ
Nordic Stocks Rose Wednesday; Better Collective Topped Leaders DJ
Transcript : Bavarian Nordic A/S, H1 2023 Earnings Call, Aug 23, 2023
Swiss stocks lead gains in Europe, data point to slowing activity RE
Nordic Stocks Rose Tuesday; Filo Topped Leaders DJ
Chart Bavarian Nordic A/S
More charts
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (95.8%) and services (4.2%). Net sales are distributed geographically as follows: the United States (26.7%), Germany (20.6%), Belgium (10.6%), France (8.5%), Canada (6.3%), the United Kingdom (5.4%), Hong Kong (3.7%), Saudi Arabia (3.2%), Australia (3.1%), Switzerland (2.2%) and other (9.7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
176.9 DKK
Average target price
280.8 DKK
Spread / Average Target
+58.73%
Consensus
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW